SEER

Seer Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$105.76M
P/E Ratio
—
EPS
$-1.22
Beta
1.51
52W High
$2.41
52W Low
$1.55
50-Day MA
$2.03
200-Day MA
$1.89
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Seer Inc

Seer, Inc., a life sciences company, is dedicated to developing and marketing products for researchers to unlock biological information. The company is headquartered in Redwood City, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$14.22M
Gross Profit (TTM)$6.78M
EBITDA$-64.85M
Operating Margin-543.00%
Return on Equity-26.50%
Return on Assets-15.30%
Revenue/Share (TTM)$0.25
Book Value$4.08
Price-to-Book0.45
Price-to-Sales (TTM)7.44
EV/Revenue0.0835
EV/EBITDA1.72
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-23.40%
Shares Outstanding$55.37M
Float$40.53M
% Insiders14.65%
% Institutions50.79%

Historical Volatility

HV 10-Day
35.54%
HV 20-Day
27.92%
HV 30-Day
24.70%
HV 60-Day
71.42%
HV Rank
10.7%

Volatility is currently expanding

Latest News

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Convention & Exhibition Centre.

GlobeNewsWire9/23/2026Neutral
Seer Announces CFO Transition

REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company's President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company.

GlobeNewsWire9/21/2026Neutral
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale

Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health

GlobeNewsWire9/16/2026Neutral
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.'s Board of Directors

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani. *** September 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani Dear Ms. Gulyani, As you know, we are significant stockholders of Seer, Inc. (“Seer” or the “Company”), collectively owning approximately 7.7% of the Company's.

Business Wire9/4/2026Neutral
Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the Company's Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Board of Directors Dear Members of the Board of Directors (the “Board”), Bradley L. Radoff and Michael Torok (together with certain of their affiliat.

Business Wire8/13/2026Neutral
Seer Q2 Earnings Call Highlights

Seer NASDAQ: SEER reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers.

MarketBeat8/12/2026Negative
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA.

GlobeNewsWire8/3/2026Neutral
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2026 on Tuesday, August 11, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire8/3/2026Neutral
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

LOS ANGELES, July 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PRNewsWire7/31/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SEER and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026